According to a market report, published by Sheer Analytics and Insights, the global anti-tuberculosis therapeutics market was valued at $1.34 billion in 2021 and it is expected to reach $2.9 billion at a CAGR of 7.2% between 2022 and 2032. The market under study is expanding as a result of factors such as the rising prevalence of tuberculosis, the government's growing awareness campaign, the collaboration of academic and private entities on the development of novel drugs, and the rise in MDR and XDR cases in emerging nations. The WHO reports that the overall success rate for treating TB was around 83%. TB is the most common infectious agent to cause death, ranking as the ninth highest cause of death globally. The illness claims more lives than HIV/AIDS does. Leading medical regulatory authorities are faced with difficulty as a result of the global burden of TB and MDR-TB. The government's and medical communities' vigorous efforts to combat TB are predicted to lead to an increase in TB diagnoses. As a result, the global market for anti-tuberculosis treatments is expanding, helped along by an increase in the prevalence of TB and MDR-TB worldwide. These primary factors are driving the market growth during the forecast period.
The market under study is expected to grow as a result of rising government initiatives to increase public awareness of tuberculosis, partnerships between academic institutions and private companies to develop novel drugs, and an increase in MDR and XDR cases in developing countries, among other factors. The market for anti-tuberculosis treatments has recently grown quickly, and this is expected to continue during the projection period. One of the top 10 global causes of death and the most common infectious disease-related cause of death is tuberculosis. Leading medical regulatory agencies face difficulty as a result of the prevalence of tuberculosis and multidrug-resistant tuberculosis around the world. Increased tuberculosis diagnoses are anticipated as a result of the government's and medical community's considerable involvement in the fight against the disease. As a result, the market for anti-tuberculosis treatments is in great demand. These primary factors are expected to drive market growth during the forecast period.
Request a free PDF sample report: https://www.sheeranalyticsandinsights.com/request-sample/anti-tuberculosis-therapeutics-market-21
However, the majority of TB cases with currently available medications can take up to 6 months of therapy. Advances in technology and the development of novel therapeutics are projected to improve the time of treating TB. Nevertheless, there is a constant need to increase patients' access to appropriate TB medicines, particularly in the areas of multidrug-resistant TB (MDR TB) and pediatric TB. This is true despite existing medications and ongoing advances in TB treatment drugs. Moreover, the market for medications to treat tuberculosis is expanding as a result of an increasing number of drug innovations. A novel medicine has been created by the nonprofit TB Alliance in the United States to treat extremely treatment-resistant tuberculosis strains.
The frequency of drug recalls is on the rise, and this is a significant factor limiting market expansion. The increasing number of product recalls caused by issues like packaging or manufacturing faults is a challenge for TB medication manufacturers. However, new developments are expected to drive market growth. Key players globally are focusing on expanding new business strategies to hold a strong position in the global market.
Some new developments in the global anti-tuberculosis therapeutics market:
- In 2019, the non-profit TB Alliance's Pretomanid has been approved in the United States for use in combination regimens with bed aquiline and linezolid for persons with XDR-TB or treatment-intolerant/non-responsive MDR-TB. A three-drug, six-month, all-oral regimen for treating patients with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive was approved under the Limited Population Route for Antibacterial and Antifungal Drugs (LPAD pathway).
- On 4th May, 2022, The World Health Organization presented its revised recommendations, which experts claim will allow patients to receive treatment in six months with cure rates close to 90%. If it is determined that a patient's TB bacilli are resistant to that class of medications, this regimen may be utilized without moxifloxacin. Individualized lengthier treatment regimens utilizing the drugs advised in current guidelines will benefit patients with severe DR-TB or those who have failed shorter treatment regimens.
According to the study, key players dominating the global anti-tuberculosis therapeutics market are AstraZeneca (U.K), Abbvie (U.S), Cipla (India), Eli Lilly (U.S), Fresenius (Germany), Johnson and Johnson (U.S), Lupin (India), Lannett (U.S), Pfizer (U.S), Merck and Co. (U.S), Novartis (Switzerland), STI Pharma (U.S), Sanofi (France), Teva Pharmaceuticals (Israel), Viatris (U.S), among others.
Browse the full report at https://www.sheeranalyticsandinsights.com/market-report-research/anti-tuberculosis-therapeutics-market-21
The Global Anti-Tuberculosis Therapeutics Market Has Been Segmented Into:
The Global Anti-Tuberculosis Therapeutics Market – by Disease Type:
- Active TB
- Latent TB
- Others
The Global Anti-Tuberculosis Therapeutics Market – by Diagnosis Type:
- Blood Tests
- Sputum Tests
- Imaging Tests
- Others
The Global Anti-Tuberculosis Therapeutics Market – by Dosage Type:
- Tablets and Capsules
- Injections
- Others
The Global Anti-Tuberculosis Therapeutics Market – Region Type:
- North America
- The U.S.
- Canada
- Mexico
- Europe
- U.K.
- France
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia
- Rest of Asia Pacific
- LAMEA
- Middle East
- Saudi Arabia
- UAE
- Others
- Latin America
- Brazil
- Chile
- Others
- Africa
- South Africa
- Egypt
- Others
No comments:
Post a Comment